Health Care Provider Bulletin

LifeLabs Service Updates 02/04/2026

Alzheimer's Aβ42/40 with p-tau217 Testing is Available at LifeLabs

Dear valued Health Care Provider,

LifeLabs is proud to support you by offering one of the industry's most comprehensive portfolios of blood-based biomarker tests for assessing dementia and Alzheimer's disease. Our portfolio includes the Aβ42/40 ratio and p-tau217 Evaluation panel, the standalone p-tau217, and the Aβ42/40 ratio.

Importantly, the LifeLabs Aβ42/40 and p-tau217 Evaluation panel is a CLIA-cleared laboratory-developed test and is distinct from the Fujirebio Lumipulse p-tau217/Aβ42 assay, as such, our test is not affected by the current quality hold on the Fujirebio assay. The LifeLabs' Aβ42/40 ratio and p-tau217 Evaluation panel provides reliable risk stratification by estimating the likelihood of amyloid PET positivity (categorized as low, indeterminate, or high).[1] Performance characteristics include:

- Sensitivity: 91%
- Specificity: 91%
- Positive predictive value: 87% (at an estimated disease prevalence of ~46%)
- Negative predictive value: 91% (at an estimated disease prevalence of ~46%)

What This Means for You

Testing for the Aβ42/40 ratio with p-tau217, using the Evaluation panel, remains available through LifeLabs. Test requests can be submitted using the Alzheimer's custom requisition form or a standard OHIP laboratory requisition form by writing test names in the "Other Tests" section.

When used for patients with mild cognitive impairment (MCI), this panel meets or exceeds the Alzheimer's CEO Initiative (CEOi) performance standards for confirmatory blood-based biomarkers.[2]

Thank you for your continued trust in our laboratory services. We remain committed to supporting your Alzheimer's testing needs with high-quality, evidence-based insights and care.

If you have any questions, please contact the LifeLabs Customer Care Centre at 1-877-849-3637.

For more information on our full Alzheimer's disease test offering, please click here.

Sincerely,

LifeLabs

1. Weber, Darren M et al. "Development and Clinical Validation of Blood-Based Multibiomarker Models for the Evaluation of Brain Amyloid Pathology." *Neurology. Clinical practice* vol. 15,6 (2025): e200546. doi:10.1212/CPJ.0000000000200546
2. https://alzdiagnostichub.org/bbm-performance-standards/